This week's Fierce Pharma is brought to you by Aldevron.

Complimentary Whitepaper Download

Hi E, check out this Fierce Whitepaper we think you'll like:

Eliminating antibiotic resistance gene transfer risks in cell & gene therapies

A solution to avoid antibiotic resistant plasmids in cell & gene therapies

As regulators double down their emphasis on safety for gene and cell therapies, antibiotic-based selection during plasmid production is under increased scrutiny. In this whitepaper, we discuss the drawbacks of antibiotic resistance that cause side effects in patients and describe a proactive strategy to:

• Meet or exceed regulator expectations
• Demonstrate value to increasingly cautious investors
• Ease Regulatory Concerns
• Shorten timelines
• Relieve manufacturing burden